PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone775-832-8500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$320.06 million
Profitability
Miscellaneous
Employees87
OptionableOptionable
PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions
What is PDL BioPharma's stock symbol?
PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."
How will PDL BioPharma's stock buyback program work?
PDL BioPharma declared that its board has approved a stock repurchase program on Monday, September 24th 2018, which permits the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 27.3% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.
How were PDL BioPharma's earnings last quarter?
PDL BioPharma Inc (NASDAQ:PDLI) announced its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported $0.07 EPS for the quarter, hitting the Zacks' consensus estimate of $0.07. The biotechnology company earned $67.90 million during the quarter. PDL BioPharma had a negative net margin of 28.41% and a positive return on equity of 7.72%. View PDL BioPharma's Earnings History.
When is PDL BioPharma's next earnings date?
What price target have analysts set for PDLI?
1 equities research analysts have issued twelve-month price targets for PDL BioPharma's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate PDL BioPharma's share price to reach $3.00 in the next year. This suggests that the stock has a possible downside of 5.7%. View Analyst Price Targets for PDL BioPharma.
What is the consensus analysts' recommendation for PDL BioPharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.
Has PDL BioPharma been receiving favorable news coverage?
Media coverage about PDLI stock has trended somewhat positive on Friday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PDL BioPharma earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
Who are some of PDL BioPharma's key competitors?
Some companies that are related to PDL BioPharma include Atara Biotherapeutics (ATRA), Spark Therapeutics (ONCE), Regenxbio (RGNX), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Sangamo Therapeutics (SGMO), Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Orchard Therapeutics (ORTX), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB) and Novavax (NVAX).
Who are PDL BioPharma's key executives?
PDL BioPharma's management team includes the folowing people:
- Mr. John Peter McLaughlin, CEO & Director (Age 67)
- Mr. Dominique P. Monnet, Pres (Age 58)
- Mr. Peter S. Garcia, VP & CFO (Age 57)
- Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 55)
- Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.
Who are PDL BioPharma's major shareholders?
Which major investors are selling PDL BioPharma stock?
Which major investors are buying PDL BioPharma stock?
How do I buy shares of PDL BioPharma?
Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PDL BioPharma's stock price today?
One share of PDLI stock can currently be purchased for approximately $3.18.
How big of a company is PDL BioPharma?
PDL BioPharma has a market capitalization of $453.99 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL BioPharma employs 87 workers across the globe.
What is PDL BioPharma's official website?
How can I contact PDL BioPharma?
PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]
MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
